Dr. Amit Narula, D.O.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 1,460
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
MD license H0071926 -
Internal Medicine Physician
OH license 58.002312
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Carroll Hospital Center Westminster, MD
Medical groups
- Mid Atlantic Pulmonary Critical Care and Sleep PC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,460
- Services billed
- 7,022
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 1,548 | 347 |
| Test to measure expiratory airflow and volume | 1,015 | 714 |
| Established patient office or other outpatient visit, 20-29 minutes | 750 | 629 |
| Established patient office or other outpatient visit, 30-39 minutes | 681 | 495 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 590 | 195 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 488 | 412 |
| Test to determine lung volumes using sensors | 321 | 316 |
| Test to examine how well the lungs exchange gases | 321 | 316 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 318 | 313 |
| New patient office or other outpatient visit, 45-59 minutes | 269 | 269 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Westminster, MD | 460 |
| Prednisone Other prescribers in Westminster, MD | 274 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Westminster, MD | 263 |
| Montelukast Sodium Other prescribers in Westminster, MD | 223 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Westminster, MD | 139 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Westminster, MD | 107 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Westminster, MD | 103 |
| Azithromycin Other prescribers in Westminster, MD | 90 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Westminster, MD | 83 |
| Methylprednisolone Other prescribers in Westminster, MD | 78 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 227 payments worth $38,847 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $20,768 |
|---|---|
| Jazz Pharmaceuticals Inc. | $10,832 |
| Viatris Specialty LLC | $3,900 |
| GlaxoSmithKline, LLC. | $577 |
| Mallinckrodt Hospital Products Inc. | $382 |
| Verona Pharma, Inc. | $323 |
| Inspire Medical Systems, Inc. | $318 |
| Axsome Therapeutics, Inc. | $317 |
| Compensation for services other than consulting (speaking, faculty) | $31,640 |
|---|---|
| Food and Beverage | $5,816 |
| Travel and Lodging | $1,002 |
| Consulting Fee | $200 |
| Education | $190 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. May 14, 2025 | Compensation for services other than consulting (speaking, faculty) XYWAV · NEUROLOGY | $9,282 |
| AstraZeneca Pharmaceuticals LP Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Sep 16, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Jan 31, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| Viatris Specialty LLC Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) YUPELRI · Anticholinergics, Inhaled | $2,203 |
| AstraZeneca Pharmaceuticals LP Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| Viatris Specialty LLC Jul 15, 2025 | Compensation for services other than consulting (speaking, faculty) YUPELRI · Anticholinergics, Inhaled | $935 |
All 20 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Viatris Specialty LLC Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) YUPELRI · Anticholinergics, Inhaled | $271 |
| AstraZeneca Pharmaceuticals LP Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $300 |
| AstraZeneca Pharmaceuticals LP Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Oct 29, 2025 | Travel and Lodging BREZTRI · Respiratory · travel to Annapolis, MD · in-kind Company’s descriptionSpeaker Expenses | $81.20 |
| AstraZeneca Pharmaceuticals LP Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Sep 16, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Sep 10, 2025 | Travel and Lodging BREZTRI · Respiratory · travel to McLean, VA · in-kind Company’s descriptionSpeaker Expenses | $81.20 |
| Jazz Pharmaceuticals Inc. Jul 25, 2025 | Education XYWAV · NEUROLOGY · in-kind | $99.99 |
| Viatris Specialty LLC Jul 15, 2025 | Compensation for services other than consulting (speaking, faculty) YUPELRI · Anticholinergics, Inhaled | $935 |
| AstraZeneca Pharmaceuticals LP Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| Jazz Pharmaceuticals Inc. Jun 10, 2025 | Travel and Lodging XYWAV · NEUROLOGY · travel to DFW AIRPORT, TX · in-kind | $60.00 |
| AstraZeneca Pharmaceuticals LP Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| Jazz Pharmaceuticals Inc. May 14, 2025 | Compensation for services other than consulting (speaking, faculty) XYWAV · NEUROLOGY | $9,282 |
| Jazz Pharmaceuticals Inc. May 2, 2025 | Travel and Lodging XYWAV · NEUROLOGY · travel to Dallas, TX · in-kind | $464 |
| Jazz Pharmaceuticals Inc. May 2, 2025 | Travel and Lodging XYWAV · NEUROLOGY · travel to Dallas, TX · in-kind | $315 |
| Avadel Cns Pharmaceuticals, LLC Apr 21, 2025 | Consulting Fee LUMRYZ · CENTRAL NERVOUS SYSTEM CNS NEUROLOGY · in-kind | $200 |
| Mallinckrodt Hospital Products Inc. Apr 8, 2025 | Education ACTHAR · IMMUNOLOGY · in-kind Company’s descriptionRelevant medical textbook or clinical reprint | $89.99 |
| Viatris Specialty LLC Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) YUPELRI · Anticholinergics, Inhaled | $2,203 |
| AstraZeneca Pharmaceuticals LP Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Jan 31, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,842 in research payments for these studies, mostly to the institutions running them.
- Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility
United Therapeutics Corporation · Completed · NCT03641677
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.